These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16846774)

  • 1. The role of bevacizumab in ovarian cancer--an evolving story.
    Aghajanian C
    Gynecol Oncol; 2006 Aug; 102(2):131-3. PubMed ID: 16846774
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [First-line bevacizumab in ovarian cancer].
    Mäenpää J
    Duodecim; 2011; 127(19):2037-44. PubMed ID: 22073535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
    Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
    Penson RT; Dizon DS; Cannistra SA; Roche MR; Krasner CN; Berlin ST; Horowitz NS; Disilvestro PA; Matulonis UA; Lee H; King MA; Campos SM
    J Clin Oncol; 2010 Jan; 28(1):154-9. PubMed ID: 19917843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.
    Walker JL
    Gynecol Oncol; 2009 Mar; 112(3):439-40. PubMed ID: 19245944
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
    Shah DK; Veith J; Bernacki RJ; Balthasar JP
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Big costs for little gain in ovarian cancer.
    Hensley ML
    J Clin Oncol; 2011 Apr; 29(10):1230-2. PubMed ID: 21383287
    [No Abstract]   [Full Text] [Related]  

  • 11. Improved survival with addition of bevacizumab to paclitaxel and carboplatin in elderly patients with non-small-cell lung cancer.
    Atkins CD
    J Clin Oncol; 2008 Apr; 26(12):2063-4; author reply 2064-5. PubMed ID: 18421066
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab for non-small-cell lung cancer.
    Sculier JP; Meert AP; Paesmans M
    N Engl J Med; 2007 Mar; 356(13):1373-4; author reply 1374-5. PubMed ID: 17396306
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab for non-small-cell lung cancer.
    Garassino MC; Hollander L; Torri V
    N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17392310
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment.
    Zorn KK
    Oncology (Williston Park); 2010 Jul; 24(8):738, 740. PubMed ID: 20718253
    [No Abstract]   [Full Text] [Related]  

  • 16. Bevacizumab for non-small-cell lung cancer.
    Sonpavde G
    N Engl J Med; 2007 Mar; 356(13):1374; author reply 1374-5. PubMed ID: 17396304
    [No Abstract]   [Full Text] [Related]  

  • 17. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cytostatic treatment of ovarian carcinoma].
    Neijt JP
    Ned Tijdschr Geneeskd; 1999 Oct; 143(44):2181-5. PubMed ID: 10578409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for non-small-cell lung cancer.
    Oxnard GR
    N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17396305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.